研究者業績

遠藤 俊輔

エンドウ シュンスケ  (Shunsuke Endo)

基本情報

所属
自治医科大学 附属さいたま医療センター センター長
学位
医学博士(自治医科大学(JMU))

J-GLOBAL ID
200901055858275340
researchmap会員ID
1000364787

1984年 筑波大学医学専門学群卒業 同病院外科レジデント
1989年 カナダ マギール大学実験医学研究部門研究員
大動脈内の血流解析 博士論文取得
1992年 自治医科大学胸部外科助手
1998年 宇都宮社会保険病院呼吸器外科科長
2000年 自治医科大学呼吸器外科講師
2004年 自治医科大学呼吸器外科助教授
2005年 自治医科大学附属さいたま医療センター呼吸器外科助教授
2008年4月 自治医科大学附属さいたま医療センター呼吸器外科教授
2008年10月 自治医科大学外科学講座呼吸器外科部門
兼 附属さいたま医療センター呼吸器外科 教授



所属学会 評議員
日本外科学会 代議員 将来計画委員 邦文誌編集委員
日本胸部外科学会評議員 学術部会委員
日本呼吸器外科学会 評議員 理事
日本呼吸器内視鏡学会 評議員
日本呼吸器学会 代議員 専門医試験委員
日本肺癌学会 評議員 X線検診部会委員
日本内視鏡外科学会評議員 学術委員
NCD 運営委員
Annals of Cardivascular Surgeon Editorial board

研究キーワード

 2

学歴

 2

MISC

 22
  • S Endo, Y Sakuma, Y Sato, Y Sohara
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY 26(5) 1042-1042 2004年11月  
  • S Endo, T Yamaguchi, N Saito, S Otani, T Hasegawa, Y Sato, Y Sohara
    ANNALS OF THORACIC SURGERY 77(5) 1745-1750 2004年5月  
    Background. The benefit of thymectomy in myasthenia gravis management is recognized but the perioperative course can fluctuate. The goal of this study was to assess the feasibility and clinical benefit of dose-escalated steroid therapy with thymectomy for nonthymornatous myasthenia gravis. Methods. We reviewed the records of 69 myasthenia gravis patients who were followed up after undergoing transsternal thymectomy with extended anterior mediastinal dissection in our hospital between 1976-2000. Forty-eight patients in the programmed treatment group who had dose-escalated and de-escalated steroid therapy during the perioperative period comprised 17 patients with ocular myasthenia gravis and 31 patients with generalized myasthenia gravis. Clinical benefits and clinical remission, which was diagnosed when the patients were symptom-free without medications for at least 1 year, were compared with those of 21 patients in the occasional treatment group who received medications occasionally over the perioperative period. Results. Postoperative respiratory failure and myasthenic crisis did not occur in the programmed treatment group but did occur in 6 patients in the occasional treatment group. Remission rates in the programmed treatment group (mean follow-up, 6.4 years) were 30% at 3 years, 38% at 5 years, and 46% at 10 years; rates in the occasional treatment group (mean follow-up, 9.6 years) were 25% at 3 years, 25% at 5 years, and 45% at 10 years. Conclusions. Programmed steroid therapy in patients with nonthymomatous myasthenia gravis is feasible and it provides clinical benefit when fluctuating symptoms occur during the perioperative period.
  • S Endo, T Yamaguchi, N Saito, S Otani, T Hasegawa, Y Sato, Y Sohara
    ANNALS OF THORACIC SURGERY 77(5) 1745-1750 2004年5月  
    Background. The benefit of thymectomy in myasthenia gravis management is recognized but the perioperative course can fluctuate. The goal of this study was to assess the feasibility and clinical benefit of dose-escalated steroid therapy with thymectomy for nonthymornatous myasthenia gravis. Methods. We reviewed the records of 69 myasthenia gravis patients who were followed up after undergoing transsternal thymectomy with extended anterior mediastinal dissection in our hospital between 1976-2000. Forty-eight patients in the programmed treatment group who had dose-escalated and de-escalated steroid therapy during the perioperative period comprised 17 patients with ocular myasthenia gravis and 31 patients with generalized myasthenia gravis. Clinical benefits and clinical remission, which was diagnosed when the patients were symptom-free without medications for at least 1 year, were compared with those of 21 patients in the occasional treatment group who received medications occasionally over the perioperative period. Results. Postoperative respiratory failure and myasthenic crisis did not occur in the programmed treatment group but did occur in 6 patients in the occasional treatment group. Remission rates in the programmed treatment group (mean follow-up, 6.4 years) were 30% at 3 years, 38% at 5 years, and 46% at 10 years; rates in the occasional treatment group (mean follow-up, 9.6 years) were 25% at 3 years, 25% at 5 years, and 45% at 10 years. Conclusions. Programmed steroid therapy in patients with nonthymomatous myasthenia gravis is feasible and it provides clinical benefit when fluctuating symptoms occur during the perioperative period.
  • 気管支学 2004年  
  • 胸部外科 57 L143-L148 2004年